This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Partnering, Business Development & Licensing
search
Drug Development

Biotech Showcase™ 2016: Interview: Enumeral aspires to take PD-1 inhibition to the next level

Posted by on 11 July 2017
Share this article

Enumeral CEO Arthur Tinkelenberg explains his company’s human-driven immune profiling platform and how it could help develop tomorrow’s checkpoint inhibitors to “The Pink Sheet” Senior Writer Emily Hayes. Enumeral’s platform allows researchers to study cells directly from patients, in order to identify those who will respond to particular drugs. In late 2014, the Cambridge, Massachusetts-based biotech secured a collaboration deal with Merck that involves using this platform to interrogate the tumor microenvironment in human colon cancer tissues, for use in predicting response to the big pharma’s immunotherapies. Much research work to date has been in rodent models, but predicting how immunomodulatory therapy works using animal models doesn’t work very well, the exec explains. Tinkelenberg also discusses his company’s lead preclinical candidate, a PD-1 inhibitor for lung cancer that will be aimed at PD-1 treatment failures.

Share this article

Sign up for Partnering, Business Development & Licensing email updates

keyboard_arrow_down